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Abstract (max 200 words) 43 
Background: The current rifampicin dose (10 mg/kg) is sub-optimal for treating tuberculosis. 44 
The PanACEA HIGHRIF1 trial evaluated pharmacokinetics and early bactericidal activity 45 
with rifampicin doses up to 40 mg/kg. Conventional statistics revealed no significant 46 
exposure-response relationship. Our objective was to explore exposure-response for high dose 47 
rifampicin using pharmacokinetic-pharmacodynamic modeling and to predict early 48 
bactericidal activity of 50 mg/kg rifampicin. 49 
Methods: Data included time-to-positivity of sputum in liquid culture from 83 tuberculosis 50 
patients treated with 10 (n=8), 20, 25, 30, 35 or 40 (n=15/group) mg/kg rifampicin for 7 days 51 
(clinicaltrials.gov, NCT01392911). We used a semi-mechanistic time-to-event approach to 52 
model the time-to-positivity data. Rifampicin exposure and baseline time-to-positivity were 53 
explored as covariates.  54 
Results: Baseline time-to-positivity was a significant covariate on the predicted initial 55 
bacterial load and rifampicin exposure was significant on bacterial kill in sputum giving 56 
increased early bactericidal activity. The 90% prediction interval for the predicted median day 57 
7 increase in time-to-positivity for 50 mg/kg rifampicin was 7.25-10.3 days.  58 
Conclusions: A significant exposure-response relationship was found between rifampicin 59 
exposure and early bactericidal activity. Clinical trial simulations showed greater early 60 
bactericidal activity for 50 mg/kg rifampicin. Our semi-mechanistic time-to-event approach is 61 
effective for studying exposure-response in tuberculosis and de-risking future drug 62 
development.  63 
Key words (3-10): Pharmacodynamics, Tuberculosis, Pharmacokinetics, Patients, Time-to-64 
positivity, Early bactericidal activity, Models, Bactericidal effect, Mycobacterium 65 
tuberculosis  66 
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Introduction 67 
Since the concept of increasing the dose of rifampicin dose for treatingment of tuberculosis 68 
was re-introduced, a battery of trials has been conducted to optimize treatment of pulmonary 69 
tuberculosis and tuberculous meningitis [1–9]. Despite this, a question remains: what is the 70 
optimal dose of rifampicin [10,11]? The answer remains unknown but some recent clinical 71 
trials data has have provided important insight. The PanACEA HIGHRIF1 trial [4] studied 72 
short-term safety, pharmacokinetics and anti-mycobacterial activity of up to 40 mg/kg 73 
rifampicin. No statistically significant relationship was determined between the rifampicin 74 
exposure and the early bactericidal activity [4] in humans despite several lines of evidence 75 
derived from in vitro and animal experiments suggesting a clear relationship between 76 
exposure and mycobacterial killing [12–15].  77 
Early bactericidal activity can be quantified using time-to-positivity in liquid culture which is 78 
defined as the time from start of incubation of a sputum specimen in a liquid culture system 79 
until a positive signal is detected. A high bacterial load is expected to lead to short time-to-80 
positivity and vice versa. 81 
Time-to-positivity reflects time-to-event data. For conventional statistics, early bactericidal 82 
activity determined using time-to-positivity is usually analyzed in the context of a series of 83 
data points from daily sputum cultures as the change in time-to-positivity per day of treatment 84 
by regression-based methods [16,17]. Two semi-mechanistic pharmacokinetic-85 
pharmacodynamic models exist treating time-to-positivity as time-to-event data [18,19].  86 
Model-based pharmacokinetic-pharmacodynamic analysis has been shown to be more 87 
powerful in terms offor defining exposure-response than conventional statistical methods 88 
[20]. Semi-mechanistic pharmacokinetic-pharmacodynamic models also allow for meaningful 89 
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extrapolation of data toby simulatinge new scenarios such as predicting early bactericidal 90 
activity of higher than observed doses which can be used to design future clinical trials. 91 
The Our objective of this study was to apply a semi-mechanistic time-to-event approach to 92 
explore the exposure-response for early bactericidal activity determined using time-to-93 
positivity in pulmonary tuberculosis patients treated with high dose rifampicin (up to 40 94 
mg/kg) and then, to simulate early bactericidal activity of 45 and 50 mg/kg rifampicin in order 95 
to inform the clinical development process of optimizing a higher rifampicin dose. 96 
  97 
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Methods 98 
Ethics 99 
The study protocol was approved by local ethical review boards and by the Medicines Control 100 
Council of South Africa and was conducted according to Good Clinical Practice. All patients 101 
provided written informed consent before enrollment in the study. 102 
Patient data 103 
Modeling was performed on one week repeated time-to-positivity data measured from sputum 104 
in patients recruited in the HIGHRIF1 trial, a prospective open-label multiple dose-rising trial 105 
registered at www.clinicaltrials.gov NCT01392911 [4]. Smear-positive pulmonary 106 
tuberculosis patients were treated with either 10 (n=8, reference arm), 20, 25, 30, 35 or 40 107 
(n=15/arm) mg/kg daily rifampicin as monotherapy for 7 days. The actual study duration was 108 
14 days with isoniazid, pyrazinamide and ethambutol in standard doses added to the high dose 109 
rifampicin for days 8-14. In this analysis, only data until day 7 was used to define the 110 
exposure-response relationship for rifampicin alone. Overnight sputum sampling was 111 
performed on two consecutive days at baseline and daily for 7 days. Time-to-positivity was 112 
determined in duplicate from each sample using a standardized liquid culture BD BACTEC™ 113 
MGIT™ mycobacterial growth indicator tube system (MGIT 960, Becton-Dickinson, Sparks, 114 
MD) in a single laboratory. The HIGHRIF1 trial is described in detail in the relevant 115 
reference references [4]. 116 
Data analysis 117 
Time-to-positivity data were analyzed with a time-to-event approach using the non-linear 118 
mixed effects modeling software NONMEM 7.3 [21] with the Laplacian estimation method. 119 
Data handling and visualization were done in R version 3.4.3 [22]. Model diagnostics were 120 
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performed in Xpose 4.6.0 [23,24], in particular visual predictive checks using PsN 4.6.12 121 
[23,25]. Models were compared based on the objective function value (OFV) using the 122 
likelihood ratio test at the 5% significance level. 123 
Time-to-positivity replicates at each time point were analyzed without averaging. Time-to-124 
positivity at baseline was included in the model as a covariate (see below). 125 
Structural model 126 
The starting point for model development was a previously developed semi-mechanistic time-127 
to-event model for time-to-positivity [19]. Briefly, the model structure was derived from 128 
underlying knowledge about (i) how the amount of viable tuberculosis bacteria changes in 129 
human sputum over time, referred to as sputum model, (ii) how tuberculosis bacteria are 130 
known to grow in a liquid culture, referred to as mycobacterial growth model, and (iii) how 131 
the mycobacterial growth relates to the probability of achieving a positive signal event in the 132 
MGIT, referred to as hazard model. The starting model included drug effect without an 133 
exposure-response relationship. 134 
Sputum models with one and two mycobacterial subpopulations were tested. The bacterial 135 
load in the single mycobacterial subpopulation model was described using the following 136 
equationby: 137 
𝐵(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵0,𝑠𝑝𝑢𝑡𝑢𝑚 × 𝑒
−𝑘𝑘𝑖𝑙𝑙×𝑡𝑡 138 
where B0,sputum is the predicted bacterial load at start of treatment, kkill is the first-order 139 
rifampicin bacterial kill rate and tt is the time after start of treatment. For the two-140 
subpopulation model the bacterial load of the first (B1) and second (B2) mycobacterial 141 
subpopulations were described by the following equations: 142 
𝐵1(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵10,𝑠𝑝𝑢𝑡𝑢𝑚 × 𝑒
−𝑘𝑘𝑖𝑙𝑙,1×𝑡𝑡  143 
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𝐵2(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵20,𝑠𝑝𝑢𝑡𝑢𝑚 × 𝑒
−𝑘𝑘𝑖𝑙𝑙,2×𝑡𝑡 144 
where 145 
𝐵(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵1(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 + 𝐵2(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 146 
where B10,sputum and B20,sputum are the predicted bacterial load at start of treatment for the 147 
subpopulations, respectively. Parameters kkill,1 and kkill,2 describe the first-order rifampicin 148 
bacterial kill rates of the subpopulations, respectively. 149 
For the mycobacterial growth model in the liquid culture container, a logistic growth model 150 
was used where the change of bacteria in the liquid culture (Bculture) over time was described 151 
using the following differential equationby: 152 
𝑑𝐵𝑐𝑢𝑙𝑡𝑢𝑟𝑒
𝑑𝑡𝑐
= 𝑘𝐺 × (𝐵𝑚𝑎𝑥 − 𝐵(𝑡𝑐)𝑐𝑢𝑙𝑡𝑢𝑟𝑒) × 𝐵𝑐𝑢𝑙𝑡𝑢𝑟𝑒 153 
where the initial bacterial load in the liquid culture were was assumed equal to the number of 154 
bacteria in sputum at the time-point of sputum sampling according to the following: 155 
𝐵(𝑡𝑐 = 0)𝑐𝑢𝑙𝑡𝑢𝑟𝑒 = 𝐵(𝑡𝑡 = 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 156 
where kG is a predicted maximal mycobacterial growth rate in the liquid, Bmax is the maximal 157 
bacterial load in the liquid culture and tc is time after inoculation of the liquid culture.  158 
Models with two different subpopulations in the liquid culture with different growth rates for 159 
each subpopulation both with and without a possible transfer between subpopulations were 160 
explored. A lag-time for the start of growth in the liquid culture was also explored 161 
implemented as a single lag time for both the one and two subpopulation models. In addition, 162 
tTime-dependencies in kG were explored including linearly decreasing kG with time on 163 
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treatment and an exponential decline from a baseline value of kG (kG,base) to a steady state 164 
value of kG (kG,ss) according to the following: 165 
𝑘(𝑡𝑡)𝐺 = 𝑘𝐺,𝑏𝑎𝑠𝑒 + (𝑘𝐺,𝑠𝑠 − 𝑘𝐺,𝑏𝑎𝑠𝑒) × (1 − 𝑒
−𝑘𝐺,𝑘×𝑡𝑡) 166 
where kG,k is the first-order time-dependent decrease of kG,base. 167 
For the hazard model the bacterial load in the liquid culture at any given time-point was equal 168 
to the hazard, h(tc), for the liquid culture to turn into a positive signal described by: 169 
ℎ(𝑡𝑐) = 𝐵(𝑡𝑐)𝑐𝑢𝑙𝑡𝑢𝑟𝑒 170 
which was used in a next step to calculate the cumulative hazard according to the following: 171 
𝐻(𝑡𝑐) = ∫ ℎ(𝑡𝑐)𝑑𝑡
𝑡𝑐
0
 172 
This finally allowed calculation of the survival, which is the probability of a sample without a 173 
positive signal at time tc using the following equation: 174 
𝑆(𝑡𝑐) = 𝑒
−𝐻(𝑡𝑐) 175 
Covariate model 176 
The individual mean time-to-positivity at baseline was not included in the estimation but was 177 
evaluated as a covariate on the predicted bacterial load at start of treatment (B0,sputum or 178 
B10,sputum and B20,sputum) as a power-relationship. The area under the plasma concentration-179 
time curve between 0 and 24 hours (AUC0-24h) at day 7 was evaluated as a covariate on the 180 
rifampicin kill rate parameters (kkill,  or kkill,1, and kkill,2). AUC0-24h was chosen over Cmax 181 
because AUC is normally used in PKPD analyses for rifampicin. Cmax and AUC0-24h are 182 
probably highly correlated and would therefore perform similarly when explored in a PKPD 183 
model. Since only once daily dosing was included in the current study design it would 184 
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probably be difficult to definitely distinguish between Cmax and AUC0-24h.  The AUC0-24h was 185 
calculated for each subject from a full 24 hour pharmacokinetics curve concentration 186 
measurements at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours  using the linear-log trapezoidal 187 
rule in Winnonlin version 5.3 (Pharsight Corp., Mountain View, CA) as described in [4]. 188 
Concentrations were measured using validated ultra performance liquid chromatography 189 
(accuracy<4%, limit of quantification= 0.13 mg/L). 190 
Stochastic model 191 
Inter-individual variability was investigated in all parameters for the sputum model as well as 192 
for the estimated lag-time for the growth in the mycobacterial growth model. Inter-occasion 193 
variability was investigated in the sputum sampling implemented as a random variability 194 
between occasions for the bacterial load inoculated in the mycobacterial growth model [19]. 195 
Model evaluation 196 
The final semi-mechanistic time-to-event model (i.e. the chosen model after structural, 197 
covariate and stochastic model evaluations) was evaluated by performing a 1000 sample 198 
bootstrap stratified on dose group to attain parameter uncertainty in all parameters. A 199 
posterior predictive check was performed by comparing the median time-to-positivity 200 
calculated from 1000 simulated trials with the observed median time-to-positivity.  201 
Clinical trial simulation of pharmacokinetics and time-to-positivity after 45 and 50 mg/kg 202 
rifampicin 203 
The final semi-mechanistic time-to-event model was used for clinical trial simulation of time-204 
to-positivity following 45 and 50 mg/kg rifampicin, respectively once daily for 7 days. 205 
Pharmacokinetics as the driver for increasing time-to-positivity were simulated for 45 and 50 206 
mg/kg and the day 7 AUC0-24h was calculated using linear-log trapezoidal rule using ncappc 207 
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0.2.1.1 within R [26] from 1000 simulated datasets using a pharmacokinetic model developed 208 
on the same patients used in this analysis [27]. For simulating pharmacokinetics, patient 209 
covariates were sampled from the observed population in a bootstrap procedure. The AUC0-210 
24hs from the 1000 simulated trialsions were used to simulate predict time-to-positivity after 211 
45 and 50 mg/kg. Baseline time-to-positivity for the simulations were sampled from a log-212 
normal distribution centered around 4.34 days with a standard deviation of 0.32 days 213 
(estimated from the observed dataset). The same study design as for the HIGHRIF1 trial was 214 
used (i.e. 15 individuals/dose level) [4].  215 
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Results 216 
Patients and data 217 
In total, 83 patients and 1102 time-to-positivity measurements were included in this 218 
analysisanalyzed. A few samples (5.2%) were excluded from the analysis; 52 samples were 219 
contaminated (various treatment days) and 8 samples were negative (all occurred before day 7 220 
and were followed by positive samples on later treatment days). Patient characteristics are 221 
summarized in Table 1. 222 
Semi-mechanistic time-to-event model 223 
The final semi-mechanistic time-to-event model included one mycobacterial subpopulation, 224 
both in for the sputum and in the mycobacterial growth models. The latter included a time-225 
varying, exponentially declining kG. Figure 1 shows the dynamics within each sub-model for 226 
a typical patient receiving 30 mg/kg. A statistically significant exposure-response relationship 227 
was identified, i.e. the parameter kkill was found to increase linearly with increasing AUC0-24h 228 
(giving increased early bactericidal activity at higher rifampicin exposures). The baseline 229 
time-to-positivity was a significant covariate on the initial bacterial load in sputum, where a 230 
high time-to-positivity gave a low initial bacterial load. The final model did not include any 231 
random inter-individual or inter-occasion variability as it was not supported by the data.  232 
Implementation of two mycobacterial subpopulations in sputum was statistically significant 233 
compared to having one subpopulation (dOFV=-37.5, p<0.00001). However, adding a two-234 
subpopulation model to a model with time-varying kG was not significant whereas a model 235 
with a one subpopulation model and an exponential decline of kG was were significantly 236 
better than a model with only one subpopulation (dOFV=-106.1, p<0.00001).  237 
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The AUC0-24h was found to significantly increase kkill with a linear relationship (dOFV=-88.7, 238 
p<0.00001). An Emax or a sigmoidal Emax model did not decrease OFV compared to the linear 239 
model. The bBaseline time-to-positivity was a significant covariate on the initial bacterial 240 
load (i.e. B0,sputum) in the sputum model (, dOFV=-357.0, p<0.00001) which was described 241 
using a power relationship. 242 
Model evaluation 243 
The final semi-mechanistic time-to-event model was able to described the observed data well 244 
which is shown inaccording to a posterior predictive check (in Figure 2). The predicted 245 
median time-to-positivity based on the final model (grey shaded area) agrees well with the 246 
observed median time-to-positivity (black lines) in all dose groups. This was also seen when 247 
performing a visual predictive check (Supplementary Figure 1). The parameter estimates and 248 
corresponding precision in estimated parameters is shown in Table 2. The parameter precision 249 
was overall low. 250 
Clinical trial simulation of pharmacokinetics and time-to-positivity after 45 and 50 mg/kg 251 
rifampicin 252 
The predictions of early bactericidal activity after 45 and 50 mg/kg rifampicin are 253 
summarized as a 90% prediction interval (PI) for the median change from baseline time-to-254 
positivity at day 7 in Figure 3 and Table 3. The observed median values are included to 255 
provide a point of reference. The median simulated day 7 AUC0-24hs (Table 3) displayed 256 
larger relative increases in AUC0-24h than the relative increases in dose due to dose-dependent 257 
bioavailability and saturable elimination [4,27].  258 
The final semi-mechanistic time-to-event model predicted a bacterial kill rate in sputum of 259 
0.0608 days-1 (90% confidence interval [CI]: 0.0345-0.0882 days-1) at 42.8 h·mg/L (median 260 
predicted AUC0-24h for 10 mg/kg) which is considerably lower than 0.481 days
-1 (90% CI: 261 
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0.273-0.698 days-1) at 338.7 h·mg/L (median predicted AUC0-24h for 40 mg/kg). This 262 
corresponds to half-lives of bacterial elimination of 11.4 vs 1.44 days, respectively. In other 263 
words, 40 mg/kg gave 7.9 times faster kill than 10 mg/kg where the AUC0-24h was also 7.9 264 
times higher for 40 mg/kg. For 50 mg/kg, the model predicted a median AUC0-24h of 481 265 
h·mg/L which corresponds to a bacterial kill rate of 0.684 days-1 (90% CI: 0.388-0.991 days-1; 266 
half-life of bacterial elimination=1.01 days).  267 
The exposure predictions are summarized in more detail in Supplementary Figure 2. 268 
Supplementary Table 1 summarizes the simulated AUC0-24hs. Supplementary Figure 3 269 
summarizes the complete time course of the predicted median time-to-positivity.  270 
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Discussion 271 
Our semi-mechanistic time-to-event model was developed to describe early bactericidal 272 
activity determined using time-to-positivity measurements from pulmonary tuberculosis 273 
patients treated with 10 to 40 mg/kg rifampicin. A statistically significant exposure-response 274 
relationship was detected between rifampicin and bacterial kill in sputum giving greater early 275 
bactericidal activity at higher exposures. Exposure-response was not detected using 276 
conventional statistics and a likely explanation for this is that in contrast to conventional 277 
statistics, we used pharmacokinetic-pharmacodynamic modeling which has been shown to be 278 
more powerful than conventional statistical methods and that we used a time-to-event 279 
approach which is reflective of time-to-positivity data. The final model described the 280 
observed data well and was used for clinical trial simulations in order to predict early 281 
bactericidal activity following 50 mg/kg rifampicin. The clinical trial simulations of 45 and 50 282 
mg/kg predict a further increase in early bactericidal activity compared with 40 mg/kg 283 
(highest observed dose). The predicted pharmacokinetic exposure (AUC0-24h) at day 7 which 284 
was the driver for increase in early bactericidal activity increased more than proportional 285 
compared to the increase in dose (Table 3) [27].  286 
The predicted early bactericidal activity expressed as a day 7 median increase in time-to-287 
positivity was 4.37-6.30 days (90% prediction intervalPI) for 40 mg/kg compared with 2.11-288 
3.97 days for 10 mg/kg (Table 3). The early bactericidal activity for 40 mg/kg is clearly 289 
greater than for 10 mg/kg but this increase in early bactericidal activity (about two-fold) is 290 
smaller than the relative increase in predicted exposure between 10 and 40 mg/kg (almost 8-291 
fold, Table 3). This may appear unexpectedly low since the final model includes a linear 292 
exposure-response relationship between exposure and bacterial kill in sputum which means 293 
that for example, an 8 times higher AUC0-24h will give 8 times greater bacterial kill. However, 294 
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the bacterial kill in sputum does not have a linear relationship with day 7 increase in time-to-295 
positivity. 296 
In this work the bacterial load in sputum and liquid culture are reported as a probability per 297 
time unit (risk of sample turning positive per day) which are difficult to interpret. This is 298 
because the model was built only using time-to-positivity measurements. The MGIT manual 299 
states that the liquid culture container contains approximately 105-106 colony forming 300 
units/ml when the system signals positive which may reflect the Bmax value. Bmax describes 301 
the maximal bacterial load in the liquid culture container. The numbers presented as risk per 302 
time bear no meaning as such but they can be viewed on a relative scale, i.e. looking at 303 
percentage change of bacterial load from the initial load. 304 
The data supported a linear exposure-response relationship between rifampicin AUC0-24h and 305 
bacterial kill in sputum. This implies that the model will predicts an increased in time-to-306 
positivity for any increase in AUC0-24h and thus a dose where no further increase in early 307 
bactericidal activity is expected cannot be predicted from this work, and neither can any 308 
limitation arising from intolerability or adverse events with higher doses. The Emax model (see 309 
e.g. page 1057 in [28]) can be used to predict maximal effect doses but was not supported by 310 
the data. When the Emax model cannot be supported in favor of a linear model, such as here, it 311 
may indicate that the data (or doses/exposures contained in the dataset) do not cover the upper 312 
end of a sigmoidal exposure-response curve. Thus our results indicate that 40 mg/kg is located 313 
in the ascending part of the exposure-response curve which is in agreementagrees with with in 314 
vitro, in vivo and clinical studies [13,29]. Once 50 mg/kg data becomes available, the model 315 
can be updated to see if an Emax model can be identified with the expanded exposure range. 316 
The Our results presented here suggest a large overlapping in the distributions of individual 317 
predicted time-to-positivity between 45 and 50 mg/kg (Figure 3) which was also reflected in 318 
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the simulated pharmacokinetic exposures (Supplementary Figure 2). Given this large overlap 319 
in response (and exposure) it may be rational to include only 50 mg/kg in a future clinical 320 
trial. This exemplifies a strength of modeling and simulation and how it can be used to better 321 
design clinical trials. 322 
The pharmacokinetic parameters of the non-linear relation of elimination with respect to dose 323 
were estimated with high precision [27]. As such, the predicted exposures at high doses are 324 
regarded as reliable. 325 
Inter-individual variability or inter-occasion variability was not supported in the final model 326 
which may be because the variability was low or that the data was unable to support it. 327 
However, variability is included through baseline time-to-positivity and exposure which were 328 
included as covariates in the final model. 329 
A sSimilar model structures has been used infor other time-to-event models for time-to-330 
positivity exist [18,19]. Chigutsa et al. [18] included two mycobacterial subpopulations 331 
whereas in our analysis we found onlymodel includes one. In contrast to our study (83 332 
patients during one week), Chigutsa et al. performed a longer and larger trial (140 patients 333 
during 8 weeks) using standard drug combination. A biphasic pattern in the time-to-positivity 334 
data over time on treatment is probably necessary to support two mycobacterial 335 
subpopulations. Time-to-positivity data following rifampicin in monotherapy may have less 336 
biphasic pattern than the standard drug combination modelled in [18] which gave insufficient 337 
support for two mycobacterial subpopulations in our model. In order to detect biphasic killing 338 
the treatment must have pronounced killing of multiple mycobacterial sub-populations which 339 
may be case for the standard combination but not for rifampicin monotherapy.  The 340 
mycobacterial growth rate in the MGIT was decreaseding with time in our final model which 341 
was also the case for the model presented bysimilar to Chigutsa et al. [18]. In the model by 342 
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Svensson and Karlsson [19] the growth rate in the MGIT remained was constant over time. 343 
Despite the use usingof time-to-positivity to develop the latter model, the bacterial load was 344 
predicted using the unit of bacteria per milliliter of sputum. This contrastsconstrats  with our 345 
model where the bacterial load is presented as a probability per time unit as described above. 346 
It was possible by Svensson and Karlsson to predict bacterial load as bacteria/ml since many 347 
samples were negative in addition to a series of assumptions by the authors (explained in 348 
[19]). In the currentour dataset, only 8 samples were negative, which was too few to use the 349 
same approach that Svensson and Karlsson used which would have allowed predicting 350 
bacterial load in the more intuitive unit ofas bacteria/ml. Thus, there are other models with 351 
some differences. However, our model is the first time-to-event model for time-to-positivity 352 
describing the short-term response for rifampicin monotherapy. 353 
More simplisticSimpler models for time-to-positivity data use linear or bi-linear regression 354 
with time as the independent variable and treattreating time-to-positivity as a continuous 355 
variable including repeated measurements [16,30–32]. Different treatments, doses or 356 
exposures can potentially be explored as predictors for the estimated coefficients for the 357 
increase in time-to-positivity. However, these simpler regression-based models have been 358 
shown to have lower powerless powerful than model-based pharmacokinetic-359 
pharmacodynamic methods for finding exposure-response for tuberculosis in general [20]. 360 
This is further supported by our semi-mechanistic time-to-event analysis which could 361 
demonstrate exposure-response but the conventional regression-based statistical analysis did 362 
not [4]. 363 
The dDay 7 AUC0-24h was used as a covariate for the rate of decline of bacterial load in 364 
sputum. Rifampicin is known to havehas time-dependent pharmacokinetics (due to an auto-365 
induction phenomenon) and the AUC0-24h will gradually decrease from day 1 and onwards 366 
[27]. This was a potential source of bias given thatsince the extent and time-course of auto-367 
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induction may differ between dosesage groups. We have however previously shown (in the 368 
same patients) that auto-induction is similar between dose groups (extent and time-course) 369 
[27]. In this work we chose not to use the predicted AUC0-24h on day 1 as this only shifts the 370 
value for the coefficient for the bacterial decline (kkill) without altering the predictions. 371 
The non-compartmental analysis AUC0-24h (i.e. non-model-based) was used here as a 372 
secondary summary variable for the pharmacokinetic exposure and input to the semi-373 
mechanistic time-to-event model. An alternative method would be to derive theAlternatively, 374 
model-based AUC0-24h and could be used as input, using the previously developed population 375 
pharmacokinetic model [27]. In this case tThe non-compartmental analysis AUC0-24h was 376 
however calculated from a full pharmacokinetic curve and with such rich sampling, non-377 
compartmental analysis AUC0-24h is expected to perform similar to model-based AUC0-24h 378 
predicted from a population pharmacokinetic model.  379 
The model was built on time-to-positivity data from patients treated for 7 days with daily 380 
rifampicin. We have used the model for extrapolation in terms of predicting early bactericidal 381 
activity for 7 days for an increased dose of (50 mg/kg), but we are unable to predict activity 382 
for periods in excess oflonger than 7 days. While our findings are certainly not discouraging 383 
for the exploration of even higher doses, no association with sterilizing activity can be made. 384 
This study defines a statistically significant short-term exposure-response relationship for up 385 
to 40 mg/kg rifampicin and shows that a further increase in early bactericidal activity can be 386 
expected beyond 40 mg/kg. 387 
In conclusion, this study has established the exposure-response between rifampicin exposure 388 
from 10 to 40 mg/kg and increase in early bactericidal activity determined using time-to-389 
positivity. These results give further weight to studying higher doses of rifampicin in longer 390 
and larger clinical trials. Model-based clinical trial simulations of pharmacokinetics and time-391 
20 
 
to-positivity following 50 mg/kg rifampicin predict further increase in early bactericidal 392 
activity compared with 40 mg/kg. 393 
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Figure legends 506 
Figure 1 Dynamics of sputum model (a), mycobacterial growth model (b) and hazard model 507 
(c) for a typical patient receiving a dose of 30 mg/kg with AUC0-24h of 298 h·mg/L and a 508 
baseline time-to-positivity of 4 days. Open squares shows the dynamics for an early (day 1) 509 
sample and open triangles show the dynamics for a late (day 7) sample. 510 
AUC0-24h, rifampicin area under the plasma concentration-time curve during 24 hours; Bsputum, 511 
predicted bacterial load in sputum; Bculture, predicted bacterial load in liquid culture 512 
Figure 2 Posterior predictive check for median time-to-positivity in each observed dose group. 513 
Black dots connected with solid black lines are observed median time-to-positivity. Shaded 514 
areas are 90% prediction interval from 1000 simulated trials. 515 
Figure 3 Model predictions of day 7 median change from baseline time-to-positivity for 516 
different doses of rifampicin monotherapy. Shaded area is 90% prediction interval based on 517 
1000 simulated trials. Observed day 7 median change from baseline time-to-positivity is 518 
shown as black dots connected by solid black lines (no model fit performed for this plot, the 519 
observed data is just overlaid the predictions). 520 
  521 
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Table legends 522 
Table 1 Summary of baseline characteristics shown as median and range for continuous 523 
variables and number and % for categorical variables 524 
Table 2 Parameter estimates from the final semi-mechanistic time-to-event model 525 
Table 3 Predicted median day 7 change from baseline time-to-positivity and AUC0-24h 526 
  527 
29 
 
Supplementary appendix 528 
Supplementary Figure 1 Kaplan-Meier visual predictive check of final model. Solid black 529 
lines are the percent negative samples. Blue shaded areas are the 95% confidence interval of 530 
1000 simulations. 531 
Supplementary Figure 2 Visual representation of the predicted and observed rifampicin non-532 
compartmental analysis area under plasma concentration time curve for 24 hours (AUC0-24h) 533 
for day 7 (left plot) and day 14 (right plot). Black dots with error bars are observed median 534 
and range of AUC0-24h and red dots with error bars are predicted median and range of AUC0-535 
24h. No model fitting was performed for the predictions, the observed data is just overlaid the 536 
predictions for reference. Red and blue shaded areas are the variability in the predicted 537 
median (red) and range (blue) shown as inter-quartile range from 1000 simulations. 538 
Supplementary Figure 3 Predictions of median time-to-positivity for 10-50 mg/kg rifampicin. 539 
The shaded areas are the 90% prediction interval of the median time-to-positivity at each 540 
time-point from 1000 simulations. The black dots connected with solid black lines are the 541 
observed median time-to-positivity (no model fit performed for this plot, the observed data is 542 
just overlaid the predictions). 543 
Supplementary Table 1 Simulated day 7 AUC0-24h values used for prediction of high dose 544 
rifampicin 545 
 546 
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Abstract (max 200 words) 43 
Background: The current rifampicin dose (10 mg/kg) is sub-optimal for treating tuberculosis. 44 
The PanACEA HIGHRIF1 trial evaluated pharmacokinetics and early bactericidal activity 45 
with rifampicin doses up to 40 mg/kg. Conventional statistics revealed no significant 46 
exposure-response relationship. Our objective was to explore exposure-response for high dose 47 
rifampicin using pharmacokinetic-pharmacodynamic modeling and to predict early 48 
bactericidal activity of 50 mg/kg rifampicin. 49 
Methods: Data included time-to-positivity of sputum in liquid culture from 83 tuberculosis 50 
patients treated with 10 (n=8), 20, 25, 30, 35 or 40 (n=15/group) mg/kg rifampicin for 7 days 51 
(clinicaltrials.gov, NCT01392911). We used a semi-mechanistic time-to-event approach to 52 
model the time-to-positivity data. Rifampicin exposure and baseline time-to-positivity were 53 
explored as covariates.  54 
Results: Baseline time-to-positivity was a significant covariate on the predicted initial 55 
bacterial load and rifampicin exposure was significant on bacterial kill in sputum giving 56 
increased early bactericidal activity. The 90% prediction interval for the predicted median day 57 
7 increase in time-to-positivity for 50 mg/kg rifampicin was 7.25-10.3 days.  58 
Conclusions: A significant exposure-response relationship was found between rifampicin 59 
exposure and early bactericidal activity. Clinical trial simulations showed greater early 60 
bactericidal activity for 50 mg/kg rifampicin.  61 
Key words (3-10): Pharmacodynamics, Tuberculosis, Pharmacokinetics, Patients, Time-to-62 
positivity, Early bactericidal activity, Models, Bactericidal effect, Mycobacterium 63 
tuberculosis  64 
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Introduction 65 
Since the concept of increasing the rifampicin dose for treating tuberculosis was re-66 
introduced, a battery of trials has been conducted to optimize treatment of pulmonary 67 
tuberculosis and tuberculous meningitis [1–9]. Despite this, a question remains: what is the 68 
optimal dose of rifampicin [10,11]? The answer remains unknown but recent clinical trials 69 
have provided important insight. PanACEA HIGHRIF1 [4] studied short-term safety, 70 
pharmacokinetics and anti-mycobacterial activity of up to 40 mg/kg rifampicin. No 71 
statistically significant relationship was determined between rifampicin exposure and early 72 
bactericidal activity [4] in humans despite several lines of evidence derived from in vitro and 73 
animal experiments suggesting a clear relationship between exposure and mycobacterial 74 
killing [12–15].  75 
Early bactericidal activity can be quantified using time-to-positivity in liquid culture which is 76 
defined as the time from start of incubation of a sputum specimen in a liquid culture system 77 
until a positive signal is detected. A high bacterial load is expected to lead to short time-to-78 
positivity and vice versa. 79 
Time-to-positivity reflects time-to-event data. For conventional statistics, early bactericidal 80 
activity determined using time-to-positivity is usually analyzed in the context of a series of 81 
data points from daily sputum cultures as the change in time-to-positivity per day of treatment 82 
by regression-based methods [16,17]. Two semi-mechanistic pharmacokinetic-83 
pharmacodynamic models exist treating time-to-positivity as time-to-event data [18,19].  84 
Model-based pharmacokinetic-pharmacodynamic analysis has been shown to be more 85 
powerful for defining exposure-response than conventional statistical methods [20]. Semi-86 
mechanistic pharmacokinetic-pharmacodynamic models also allow for extrapolation by 87 
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simulating new scenarios such as predicting early bactericidal activity of higher than observed 88 
doses which can be used to design future clinical trials. 89 
Our objective was to apply a semi-mechanistic time-to-event approach to explore the 90 
exposure-response for early bactericidal activity determined using time-to-positivity in 91 
pulmonary tuberculosis patients treated with high dose rifampicin (up to 40 mg/kg) and then, 92 
to simulate early bactericidal activity of 45 and 50 mg/kg rifampicin in order to inform the 93 
clinical development process of optimizing a higher rifampicin dose. 94 
  95 
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Methods 96 
Ethics 97 
The study was approved by local ethical review boards and by the Medicines Control Council 98 
of South Africa and was conducted according to Good Clinical Practice. All patients provided 99 
written informed consent before enrollment in the study. 100 
Patient data 101 
Modeling was performed on one week repeated time-to-positivity data measured from sputum 102 
in patients recruited in HIGHRIF1, a prospective open-label multiple dose-rising trial 103 
registered at www.clinicaltrials.gov NCT01392911 [4]. Smear-positive pulmonary 104 
tuberculosis patients were treated with either 10 (n=8, reference arm), 20, 25, 30, 35 or 40 105 
(n=15/arm) mg/kg daily rifampicin as monotherapy for 7 days. The actual study duration was 106 
14 days with isoniazid, pyrazinamide and ethambutol in standard doses added to the high dose 107 
rifampicin for days 8-14. In this analysis, only data until day 7 was used to define the 108 
exposure-response relationship for rifampicin alone. Overnight sputum sampling was 109 
performed on two consecutive days at baseline and daily for 7 days. Time-to-positivity was 110 
determined in duplicate from each sample using a standardized liquid culture BD BACTEC™ 111 
MGIT™ mycobacterial growth indicator tube system (MGIT 960, Becton-Dickinson, Sparks, 112 
MD) in a single laboratory. HIGHRIF1 is described in detail in the relevant reference [4]. 113 
Data analysis 114 
Time-to-positivity data were analyzed with a time-to-event approach using the non-linear 115 
mixed effects modeling software NONMEM 7.3 [21] with the Laplacian estimation method. 116 
Data handling and visualization were done in R version 3.4.3 [22]. Model diagnostics were 117 
performed in Xpose 4.6.0 [23,24], in particular visual predictive checks using PsN 4.6.12 118 
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[23,25]. Models were compared based on the objective function value (OFV) using the 119 
likelihood ratio test at the 5% significance level. 120 
Time-to-positivity replicates at each time point were analyzed without averaging. Time-to-121 
positivity at baseline was included in the model as a covariate (see below). 122 
Structural model 123 
The starting point for model development was a previously developed semi-mechanistic time-124 
to-event model for time-to-positivity [19]. Briefly, the model structure was derived from 125 
underlying knowledge about (i) how the amount of viable tuberculosis bacteria changes in 126 
human sputum over time, referred to as sputum model, (ii) how tuberculosis bacteria are 127 
known to grow in a liquid culture, referred to as mycobacterial growth model, and (iii) how 128 
the mycobacterial growth relates to the probability of achieving a positive signal event in the 129 
MGIT, referred to as hazard model. The starting model included drug effect without an 130 
exposure-response relationship. 131 
Sputum models with one and two mycobacterial subpopulations were tested. The bacterial 132 
load in the single mycobacterial subpopulation model was described by: 133 
𝐵(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵0,𝑠𝑝𝑢𝑡𝑢𝑚 × 𝑒
−𝑘𝑘𝑖𝑙𝑙×𝑡𝑡 134 
where B0,sputum is the predicted bacterial load at start of treatment, kkill is the first-order 135 
rifampicin bacterial kill rate and tt is the time after start of treatment. For the two-136 
subpopulation model the bacterial load of the first (B1) and second (B2) mycobacterial 137 
subpopulations were described by: 138 
𝐵1(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵10,𝑠𝑝𝑢𝑡𝑢𝑚 × 𝑒
−𝑘𝑘𝑖𝑙𝑙,1×𝑡𝑡  139 
𝐵2(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵20,𝑠𝑝𝑢𝑡𝑢𝑚 × 𝑒
−𝑘𝑘𝑖𝑙𝑙,2×𝑡𝑡 140 
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where 141 
𝐵(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵1(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 + 𝐵2(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 142 
where B10,sputum and B20,sputum are the predicted bacterial load at start of treatment for the 143 
subpopulations, respectively. Parameters kkill,1 and kkill,2 describe the first-order rifampicin 144 
bacterial kill rates of the subpopulations, respectively. 145 
For the mycobacterial growth model in the liquid culture container, a logistic growth model 146 
was used where the change of bacteria in the liquid culture (Bculture) over time was described 147 
by: 148 
𝑑𝐵𝑐𝑢𝑙𝑡𝑢𝑟𝑒
𝑑𝑡𝑐
= 𝑘𝐺 × (𝐵𝑚𝑎𝑥 − 𝐵(𝑡𝑐)𝑐𝑢𝑙𝑡𝑢𝑟𝑒) × 𝐵𝑐𝑢𝑙𝑡𝑢𝑟𝑒 149 
where the initial bacterial load in the liquid culture was assumed equal to the number of 150 
bacteria in sputum at the time-point of sputum sampling according to: 151 
𝐵(𝑡𝑐 = 0)𝑐𝑢𝑙𝑡𝑢𝑟𝑒 = 𝐵(𝑡𝑡 = 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 𝑝𝑜𝑖𝑛𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 152 
where kG is a predicted maximal mycobacterial growth rate in the liquid, Bmax is the maximal 153 
bacterial load in the liquid culture and tc is time after inoculation of the liquid culture.  154 
Models with two subpopulations in the liquid culture with different growth rates for each 155 
subpopulation both with and without a possible transfer between subpopulations were 156 
explored. A lag-time for start of growth in the liquid culture was explored as a single lag time 157 
for both the one and two subpopulation models. Time-dependencies in kG were explored 158 
including linearly decreasing kG with time on treatment and an exponential decline from a 159 
baseline value of kG (kG,base) to a steady state value of kG (kG,ss) according to: 160 
𝑘(𝑡𝑡)𝐺 = 𝑘𝐺,𝑏𝑎𝑠𝑒 + (𝑘𝐺,𝑠𝑠 − 𝑘𝐺,𝑏𝑎𝑠𝑒) × (1 − 𝑒
−𝑘𝐺,𝑘×𝑡𝑡) 161 
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where kG,k is the first-order time-dependent decrease of kG,base. 162 
For the hazard model the bacterial load in the liquid culture at any given time-point was equal 163 
to the hazard, h(tc), for the liquid culture to turn into a positive signal described by: 164 
ℎ(𝑡𝑐) = 𝐵(𝑡𝑐)𝑐𝑢𝑙𝑡𝑢𝑟𝑒 165 
which was used in a next step to calculate the cumulative hazard according to: 166 
𝐻(𝑡𝑐) = ∫ ℎ(𝑡𝑐)𝑑𝑡
𝑡𝑐
0
 167 
This finally allowed calculation of the survival, which is the probability of a sample without a 168 
positive signal at time tc using the following equation: 169 
𝑆(𝑡𝑐) = 𝑒
−𝐻(𝑡𝑐) 170 
Covariate model 171 
The individual mean time-to-positivity at baseline was not included in the estimation but was 172 
evaluated as a covariate on the predicted bacterial load at start of treatment (B0,sputum or 173 
B10,sputum and B20,sputum) as a power-relationship. The area under the plasma concentration-174 
time curve between 0 and 24 hours (AUC0-24h) at day 7 was evaluated as a covariate on the 175 
rifampicin kill rate parameters (kkill or kkill,1 and kkill,2). AUC0-24h was chosen over Cmax 176 
because AUC is normally used in PKPD analyses for rifampicin. Cmax and AUC0-24h are 177 
probably highly correlated and would therefore perform similarly when explored in a PKPD 178 
model. Since only once daily dosing was included in the current study design it would 179 
probably be difficult to definitely distinguish between Cmax and AUC0-24h.  The AUC0-24h was 180 
calculated for each subject from  concentration measurements at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 181 
and 24 hours using the linear-log trapezoidal rule in Winnonlin version 5.3 (Pharsight Corp., 182 
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Mountain View, CA) as described in [4]. Concentrations were measured using validated ultra 183 
performance liquid chromatography (accuracy<4%, limit of quantification= 0.13 mg/L). 184 
Stochastic model 185 
Inter-individual variability was investigated in all parameters for the sputum model as well as 186 
for the estimated lag-time for the growth in the mycobacterial growth model. Inter-occasion 187 
variability was investigated in the sputum sampling implemented as a random variability 188 
between occasions for the bacterial load inoculated in the mycobacterial growth model [19]. 189 
Model evaluation 190 
The final semi-mechanistic time-to-event model (i.e. the chosen model after structural, 191 
covariate and stochastic model evaluations) was evaluated by performing a 1000 sample 192 
bootstrap stratified on dose group to attain parameter uncertainty. A posterior predictive check 193 
was performed by comparing the median time-to-positivity calculated from 1000 simulated 194 
trials with the observed median time-to-positivity.  195 
Clinical trial simulation of pharmacokinetics and time-to-positivity after 45 and 50 mg/kg 196 
rifampicin 197 
The final semi-mechanistic time-to-event model was used for clinical trial simulation of time-198 
to-positivity following 45 and 50 mg/kg rifampicin, respectively once daily for 7 days. 199 
Pharmacokinetics as the driver for increasing time-to-positivity were simulated for 45 and 50 200 
mg/kg and the day 7 AUC0-24h was calculated using linear-log trapezoidal rule using ncappc 201 
0.2.1.1 within R [26] from 1000 simulated datasets using a pharmacokinetic model developed 202 
on the same patients used in this analysis [27]. For simulating pharmacokinetics, patient 203 
covariates were sampled from the observed population in a bootstrap procedure. The AUC0-204 
24hs from the 1000 simulations were used to predict time-to-positivity after 45 and 50 mg/kg. 205 
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Baseline time-to-positivity for the simulations were sampled from a log-normal distribution 206 
centered around 4.34 days with a standard deviation of 0.32 days (estimated from the 207 
observed dataset). The same study design as for the HIGHRIF1 trial was used (i.e. 15 208 
individuals/dose level) [4].  209 
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Results 210 
Patients and data 211 
In total, 83 patients and 1102 time-to-positivity measurements were analyzed. A few samples 212 
(5.2%) were excluded from the analysis; 52 samples were contaminated (various treatment 213 
days) and 8 samples were negative (all occurred before day 7 and were followed by positive 214 
samples on later treatment days). Patient characteristics are summarized in Table 1. 215 
Semi-mechanistic time-to-event model 216 
The final semi-mechanistic time-to-event model included one mycobacterial subpopulation, 217 
both for the sputum and mycobacterial growth models. The latter included a time-varying, 218 
exponentially declining kG. Figure 1 shows the dynamics within each sub-model for a typical 219 
patient receiving 30 mg/kg. A statistically significant exposure-response relationship was 220 
identified, i.e. the parameter kkill was found to increase linearly with increasing AUC0-24h 221 
(giving increased early bactericidal activity at higher rifampicin exposures). The baseline 222 
time-to-positivity was a significant covariate on the initial bacterial load in sputum, where a 223 
high time-to-positivity gave a low initial bacterial load. The final model did not include any 224 
random inter-individual or inter-occasion variability as it was not supported by the data.  225 
Implementation of two mycobacterial subpopulations in sputum was statistically significant 226 
compared to having one subpopulation (dOFV=-37.5, p<0.00001). However, adding a two-227 
subpopulation model to a model with time-varying kG was not significant whereas a model 228 
with a one subpopulation model and an exponential decline of kG was significantly better than 229 
a model with only one subpopulation (dOFV=-106.1, p<0.00001).  230 
The AUC0-24h was found to significantly increase kkill with a linear relationship (dOFV=-88.7, 231 
p<0.00001). An Emax or a sigmoidal Emax model did not decrease OFV compared to the linear 232 
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model. Baseline time-to-positivity was a significant covariate on the initial bacterial load (, 233 
dOFV=-357.0, p<0.00001) which was described using a power relationship. 234 
Model evaluation 235 
The final semi-mechanistic time-to-event model described the observed data well according to 236 
a posterior predictive check (Figure 2). The predicted median time-to-positivity based on the 237 
final model (grey shaded area) agrees well with the observed median time-to-positivity (black 238 
lines) in all dose groups. This was also seen when performing a visual predictive check 239 
(Supplementary Figure 1). The parameter estimates and corresponding precision is shown in 240 
Table 2. The parameter precision was overall low. 241 
Clinical trial simulation of pharmacokinetics and time-to-positivity after 45 and 50 mg/kg 242 
rifampicin 243 
The predictions of early bactericidal activity after 45 and 50 mg/kg rifampicin are 244 
summarized as a 90% prediction interval (PI) for the median change from baseline time-to-245 
positivity at day 7 in Figure 3 and Table 3. The observed median values are included to 246 
provide a point of reference. The median simulated day 7 AUC0-24hs (Table 3) displayed 247 
larger relative increases in AUC0-24h than the relative increases in dose due to dose-dependent 248 
bioavailability and saturable elimination [4,27].  249 
The final semi-mechanistic time-to-event model predicted a bacterial kill rate in sputum of 250 
0.0608 days-1 (90% confidence interval [CI]: 0.0345-0.0882 days-1) at 42.8 h·mg/L (median 251 
predicted AUC0-24h for 10 mg/kg) which is considerably lower than 0.481 days
-1 (90% CI: 252 
0.273-0.698 days-1) at 338.7 h·mg/L (median predicted AUC0-24h for 40 mg/kg). This 253 
corresponds to half-lives of bacterial elimination of 11.4 vs 1.44 days, respectively. In other 254 
words, 40 mg/kg gave 7.9 times faster kill than 10 mg/kg where the AUC0-24h was also 7.9 255 
times higher for 40 mg/kg. For 50 mg/kg, the model predicted a median AUC0-24h of 481 256 
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h·mg/L which corresponds to a bacterial kill rate of 0.684 days-1 (90% CI: 0.388-0.991 days-1; 257 
half-life of bacterial elimination=1.01 days).  258 
The exposure predictions are summarized in more detail in Supplementary Figure 2. 259 
Supplementary Table 1 summarizes the simulated AUC0-24hs. Supplementary Figure 3 260 
summarizes the complete time course of the predicted median time-to-positivity.  261 
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Discussion 262 
Our semi-mechanistic time-to-event model was developed to describe early bactericidal 263 
activity determined using time-to-positivity measurements from pulmonary tuberculosis 264 
patients treated with 10 to 40 mg/kg rifampicin. A statistically significant exposure-response 265 
relationship was detected between rifampicin and bacterial kill in sputum giving greater early 266 
bactericidal activity at higher exposures. Exposure-response was not detected using 267 
conventional statistics and a likely explanation for this is that in contrast to conventional 268 
statistics, we used pharmacokinetic-pharmacodynamic modeling which has been shown to be 269 
more powerful than conventional statistical methods and that we used a time-to-event 270 
approach which is reflective of time-to-positivity data. The final model described the 271 
observed data well and was used for clinical trial simulations in order to predict early 272 
bactericidal activity following 50 mg/kg rifampicin. The clinical trial simulations of 45 and 50 273 
mg/kg predict a further increase in early bactericidal activity compared with 40 mg/kg 274 
(highest observed dose). The predicted pharmacokinetic exposure (AUC0-24h) at day 7 which 275 
was the driver for increase in early bactericidal activity increased more than proportional 276 
compared to the increase in dose (Table 3) [27].  277 
The predicted early bactericidal activity expressed as a day 7 median increase in time-to-278 
positivity was 4.37-6.30 days (90% PI) for 40 mg/kg compared with 2.11-3.97 days for 10 279 
mg/kg (Table 3). The early bactericidal activity for 40 mg/kg is clearly greater than for 10 280 
mg/kg but this increase in early bactericidal activity (about two-fold) is smaller than the 281 
relative increase in predicted exposure between 10 and 40 mg/kg (almost 8-fold, Table 3). 282 
This may appear unexpectedly low since the final model includes a linear exposure-response 283 
relationship between exposure and bacterial kill in sputum which means that for example, an 284 
8 times higher AUC0-24h will give 8 times greater bacterial kill. However, the bacterial kill in 285 
sputum does not have a linear relationship with day 7 increase in time-to-positivity. 286 
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In this work the bacterial load in sputum and liquid culture are reported as a probability per 287 
time unit (risk of sample turning positive per day) which are difficult to interpret. This is 288 
because the model was built only using time-to-positivity measurements. The MGIT manual 289 
states that the liquid culture container contains approximately 105-106 colony forming 290 
units/ml when the system signals positive which may reflect the Bmax value. Bmax describes 291 
the maximal bacterial load in the liquid culture container. The numbers presented as risk per 292 
time bear no meaning as such but they can be viewed on a relative scale, i.e. looking at 293 
percentage change of bacterial load from the initial load. 294 
The data supported a linear exposure-response relationship between rifampicin AUC0-24h and 295 
bacterial kill in sputum. This implies that the model predicts increased time-to-positivity for 296 
any increase in AUC0-24h and thus a dose where no further increase in early bactericidal 297 
activity is expected cannot be predicted from this work, and neither can any limitation arising 298 
from intolerability or adverse events with higher doses. The Emax model (see e.g. page 1057 in 299 
[28]) can be used to predict maximal effect doses but was not supported. When the Emax 300 
model cannot be supported in favor of a linear model it may indicate that the data (or 301 
doses/exposures) do not cover the upper end of a sigmoidal exposure-response curve. Thus 302 
our results indicate that 40 mg/kg is located in the ascending part of the exposure-response 303 
curve which agrees with with in vitro, in vivo and clinical studies [13,29]. Once 50 mg/kg 304 
data becomes available, the model can be updated to see if an Emax model can be identified. 305 
Our results suggest overlapping distributions of individual predicted time-to-positivity 306 
between 45 and 50 mg/kg (Figure 3) which was also reflected in the simulated 307 
pharmacokinetic exposures (Supplementary Figure 2). Given this large overlap in response 308 
(and exposure) it may be rational to include only 50 mg/kg in a future clinical trial. This 309 
exemplifies a strength of modeling and simulation and how it can be used to better design 310 
clinical trials. 311 
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The pharmacokinetic parameters of the non-linear relation of elimination with respect to dose 312 
were estimated with high precision [27]. As such, the predicted exposures at high doses are 313 
regarded as reliable. 314 
Inter-individual variability or inter-occasion variability was not supported in the final model 315 
which may be because the variability was low or that the data was unable to support it. 316 
However, variability is included through baseline time-to-positivity and exposure which were 317 
included as covariates in the final model.Similar model structures for other models for time-318 
to-positivity exist [18,19]. Chigutsa et al. [18] included two mycobacterial subpopulations 319 
whereas our model includes one. In contrast to our study (83 patients during one week), 320 
Chigutsa et al. performed a longer and larger trial (140 patients during 8 weeks) using 321 
standard drug combination. A biphasic pattern in the time-to-positivity data over time on 322 
treatment is probably necessary to support two mycobacterial subpopulations. Time-to-323 
positivity data following rifampicin in monotherapy may have less biphasic pattern than the 324 
standard drug combination modelled in [18] which gave insufficient support for two 325 
mycobacterial subpopulations in our model. In order to detect biphasic killing the treatment 326 
must have pronounced killing of multiple mycobacterial sub-populations which may be case 327 
for the standard combination but not for rifampicin monotherapy. The mycobacterial growth 328 
rate in the MGIT decreased with time in our model similar to Chigutsa et al. [18]. In the 329 
model by Svensson and Karlsson [19] the growth rate was constant. Despite using time-to-330 
positivity to develop the latter model, the bacterial load was predicted using the unit of 331 
bacteria per milliliter of sputum. This contrasts our model where the bacterial load is 332 
presented as a probability per time unit. It was possible by Svensson and Karlsson to predict 333 
bacterial load as bacteria/ml since many samples were negative in addition to a series of 334 
assumptions by the authors (explained in [19]). In our dataset, 8 samples were negative, too 335 
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few to use the approach that Svensson and Karlsson used which would allow predicting 336 
bacterial load as bacteria/ml. 337 
Simpler models for time-to-positivity data use linear or bi-linear regression with time as the 338 
independent variable and treat time-to-positivity as a continuous variable including repeated 339 
measurements [16,30–32]. Different treatments, doses or exposures can be explored as 340 
predictors for coefficients for increase in time-to-positivity. However, these simpler 341 
regression-based models less powerful than model-based pharmacokinetic-pharmacodynamic 342 
methods for finding exposure-response for tuberculosis [20]. This is further supported by our 343 
semi-mechanistic time-to-event analysis which could demonstrate exposure-response but the 344 
conventional regression-based statistical analysis did not [4]. 345 
Day 7 AUC0-24h was a covariate for the rate of decline of bacterial load in sputum. Rifampicin 346 
has time-dependent pharmacokinetics (due to auto-induction) and the AUC0-24h will gradually 347 
decrease from day 1 and onwards [27]. This was a potential source of bias since the extent 348 
and time-course of auto-induction may differ between doses. We have however shown (in the 349 
same patients) that auto-induction is similar between dose groups (extent and time-course) 350 
[27]. In this work we chose not to use the predicted AUC0-24h on day 1 as this only shifts the 351 
value for the coefficient for the bacterial decline (kkill) without altering the predictions. 352 
The non-compartmental analysis AUC0-24h (i.e. non-model-based) was used here as a 353 
secondary summary variable for the pharmacokinetic exposure and input to the semi-354 
mechanistic time-to-event model. Alternatively, model-based AUC0-24h could be used as 355 
input, using the previously developed population pharmacokinetic model [27]. The non-356 
compartmental analysis AUC0-24h was however calculated from a full pharmacokinetic curve 357 
and with such rich sampling, non-compartmental analysis AUC0-24h is expected to perform 358 
similar to model-based AUC0-24h.  359 
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The model was built on time-to-positivity data from patients treated for 7 days with daily 360 
rifampicin. We have used the model for extrapolation in terms of predicting early bactericidal 361 
activity for 7 days for an increased dose (50 mg/kg), but we are unable to predict activity 362 
longer than 7 days. While our findings are certainly not discouraging for the exploration of 363 
even higher doses, no association with sterilizing activity can be made. This study defines a 364 
statistically significant short-term exposure-response relationship for up to 40 mg/kg 365 
rifampicin and shows that a further increase in early bactericidal activity can be expected 366 
beyond 40 mg/kg. 367 
In conclusion, this study has established the exposure-response between rifampicin exposure 368 
from 10 to 40 mg/kg and increase in early bactericidal activity determined using time-to-369 
positivity. These results give further weight to studying higher doses of rifampicin in longer 370 
and larger clinical trials. Model-based clinical trial simulations of pharmacokinetics and time-371 
to-positivity following 50 mg/kg rifampicin predict further increase in early bactericidal 372 
activity compared with 40 mg/kg. 373 
  374 
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Figure legends 486 
Figure 1 Dynamics of sputum model (a), mycobacterial growth model (b) and hazard model 487 
(c) for a typical patient receiving a dose of 30 mg/kg with AUC0-24h of 298 h·mg/L and a 488 
baseline time-to-positivity of 4 days. Open squares shows the dynamics for an early (day 1) 489 
sample and open triangles show the dynamics for a late (day 7) sample. 490 
AUC0-24h, rifampicin area under the plasma concentration-time curve during 24 hours; Bsputum, 491 
predicted bacterial load in sputum; Bculture, predicted bacterial load in liquid culture 492 
Figure 2 Posterior predictive check for median time-to-positivity in each observed dose group. 493 
Black dots connected with solid black lines are observed median time-to-positivity. Shaded 494 
areas are 90% prediction interval from 1000 simulated trials. 495 
Figure 3 Model predictions of day 7 median change from baseline time-to-positivity for 496 
different doses of rifampicin monotherapy. Shaded area is 90% prediction interval based on 497 
1000 simulated trials. Observed day 7 median change from baseline time-to-positivity is 498 
shown as black dots connected by solid black lines (no model fit performed for this plot, the 499 
observed data is just overlaid the predictions). 500 
  501 
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Table legends 502 
Table 1 Summary of baseline characteristics shown as median and range for continuous 503 
variables and number and % for categorical variables 504 
Table 2 Parameter estimates from the final semi-mechanistic time-to-event model 505 
Table 3 Predicted median day 7 change from baseline time-to-positivity and AUC0-24h 506 
  507 
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Supplementary appendix 508 
Supplementary Figure 1 Kaplan-Meier visual predictive check of final model. Solid black 509 
lines are the percent negative samples. Blue shaded areas are the 95% confidence interval of 510 
1000 simulations. 511 
Supplementary Figure 2 Visual representation of the predicted and observed rifampicin non-512 
compartmental analysis area under plasma concentration time curve for 24 hours (AUC0-24h) 513 
for day 7 (left plot) and day 14 (right plot). Black dots with error bars are observed median 514 
and range of AUC0-24h and red dots with error bars are predicted median and range of AUC0-515 
24h. No model fitting was performed for the predictions, the observed data is just overlaid the 516 
predictions for reference. Red and blue shaded areas are the variability in the predicted 517 
median (red) and range (blue) shown as inter-quartile range from 1000 simulations. 518 
Supplementary Figure 3 Predictions of median time-to-positivity for 10-50 mg/kg rifampicin. 519 
The shaded areas are the 90% prediction interval of the median time-to-positivity at each 520 
time-point from 1000 simulations. The black dots connected with solid black lines are the 521 
observed median time-to-positivity (no model fit performed for this plot, the observed data is 522 
just overlaid the predictions). 523 
Supplementary Table 1 Simulated day 7 AUC0-24h values used for prediction of high dose 524 
rifampicin 525 
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Table 1 Summary of baseline patient characteristics shown as median and range for continuous variables and number and % for categorical 
variables 
Parameter All 10 mg/kg 20 mg/kg 25 mg/kg 30 mg/kg 35 mg/kg 40 mg/kg 
N 83 8 15 15 15 15 15 
Weight (kg)  53.9 (40.2-
84.2) 
56.9 (46.8-
64.9) 
52.6 (41.8-
62.7) 
52.8 (40.2-
67.9) 
54.0 (45.7-
84.2) 
57.0 (40.5-
74.0) 
58.9 (46.7-
64.8) 
Age (years)  31.0 (18.0-
59.0) 
27.5 (19.0-
49.0) 
27.0 (18.0-
46.0) 
25.0 (19.0-
46.0) 
40.0 (19.0-
59.0) 
37.0 (21.0-
59.0) 
34.0 (23.0-
58.0) 
Body mass index 
(kg/m2) 
19.4 (14.7-
30.9) 
20.5 (15.8-
26.3) 
18.6 (16.8-
26.2) 
19.3 (15.1-
25.2) 
20.9 (16.4-
30.9) 
19.4 (14.7-
25.2) 
19.4 (17.2-
19.4) 
Patients with male 
sex 
59 (71.1) 6 (75.0) 11 (73.3) 10 (66.7) 11 (73.3) 10 (66.7) 11 (73.3) 
Patients with black 
race* 
38 (45.8) 3 (37.5) 7 (46.7) 4 (26.4) 9 (60.0) 5 (33.3) 10 (66.7) 
Patients with 
colored race* 
45 (54.2) 5 (62.5) 8 (53.3) 11 (73.3) 6 (40.0) 10 (66.7) 5 (33.3) 
Table 1
Patients with HIV-
infection (%) 
3 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (13.3) 1 (6.7) 0 (0.0) 
Baseline time-to-
positivity (days) 
4.0 (2.2-18.2) 4.0 (3.3-5.2) 4.9 (3.0-9.1) 4.0 (3.4-6.5) 4.0 (2.9-6.3) 3.9 (2.6-18.2) 4.0 (2.2-7.6) 
Day 7 AUC0-24h 
(h·mg/L) 
241 (34-847) 43 (34-53) 155 (96-221) 178 (134-380) 298 (177-781) 321 (145-555) 357 (201-847) 
*“Colored race” is a population group genetically descended from South-East Asia, whereas “black race” refers to African natives. 
Abbreviations: AUC0-24h, area under the plasma concentration-time curve during 24 hours 
Table 2 Parameter estimates from the final semi-mechanistic time-to-event model 
 
Parameter Description Estimate 
90% confidence 
interval2 
S
p
u
tu
m
 m
o
d
el
 
B0,culture (risk·day
-1) 3 Baseline bacterial load 1.40·10-4 
1.67·10-5 – 
8.78·10-4 
ΘTTP 
Effect of baseline time-
to-positivity on B0 
-7.13 -9.30 - -5.18 
kkill (L·h
-1·mg-1·day-1) 
First-order rifampicin 
bacterial kill rate 
1.42·10-3 
8.06·10-4 – 
2.06·10-3 
M
y
co
b
a
ct
er
ia
l 
g
ro
w
th
 m
o
d
el
 
kG,base (day
-1) 
Baseline mycobacterial 
growth rate 
4.90 3.18 - 6.52 
kG,ss (day
-1) 
Steady state 
mycobacterial growth 
rate 
2.74 1.57 – 3.78 
kG,k (day
-1) 
Rate constant for 
decrease of 
mycobacterial growth 
rate 
0.580 0.387 – 0.870 
Bmax (risk·day
-1) 3 
Maximal bacterial load 
in liquid container 
0.523 0.459 - 0.665 
1Mathematical structure for the final model: 
𝐵(𝑡𝑡)𝑠𝑝𝑢𝑡𝑢𝑚 = 𝐵0,𝑠𝑝𝑢𝑡𝑢𝑚 × (
𝑇𝑇𝑃𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑚𝑒𝑑𝑖𝑎𝑛(𝑇𝑇𝑃𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)
)
Θ𝑇𝑇𝑃
× 𝑒−𝑘𝑘𝑖𝑙𝑙×𝐴𝑈𝐶0−24ℎ×𝑡𝑡 (sputum model) 
Table 2
𝑑𝐵𝑐𝑢𝑙𝑡𝑢𝑟𝑒
𝑑𝑡𝑐
= (𝑘𝐺,𝑏𝑎𝑠𝑒 + (𝑘𝐺,𝑠𝑠 − 𝑘𝐺,𝑏𝑎𝑠𝑒) × (1 − 𝑒
−𝑘𝐺,𝑘×𝑡𝑡)) × (𝐵𝑚𝑎𝑥 − 𝐵(𝑡𝑐)𝑐𝑢𝑙𝑡𝑢𝑟𝑒) ×
𝐵𝑐𝑢𝑙𝑡𝑢𝑟𝑒 (mycobacterial growth model) 
ℎ(𝑡𝑐) = 𝐵(𝑡𝑐)𝑐𝑢𝑙𝑡𝑢𝑟𝑒 (hazard model) 
2Obtained from a 1000 sample non-parametric bootstrap, 3Risk refers to risk of a positive 
signal from the liquid culture system 
Table 3 Predicted median day 7 change from baseline time-to-positivity and AUC0-24h 
Dose 
(mg/kg) 
Median day 7 change from baseline 
time-to-positivity (days) 
Median day 7 AUC0-24h (h·mg/L) 
Observed Predicted* Predicted 
% increase in AUC0-
24h from 10 mg/kg 
10 2.38 2.11 - 3.97 42.8 - 
20 3.87 3.03 - 4.49 139.2 225.2 
25 4.31 3.26 - 4.85 172.7 303.5 
30 5.42 3.63 - 5.16 226.3 429.4 
35 4.51 4.07 - 5.76 286.2 568.7 
40 5.89 4.37 - 6.30 338.7 691.4 
45 - 4.86 - 6.85 413.2 865.4 
50 - 5.32 - 7.48 481.4 1024.8 
*90% prediction interval based on 1000 simulated datasets 
Abbreviations: AUC0-24h, area under the plasma concentration-time curve during 24 hours 
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Figure legend 
Supplementary Figure 1 Kaplan-Meier visual predictive check of final model. Solid black 
lines are the percent negative samples. Blue shaded areas are the 95% confidence interval of 
1000 simulations. 
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Figure legend 
Supplementary Figure 3 Predictions of median time-to-positivity for 10-50 mg/kg rifampicin. 
The shaded areas are the 90% prediction interval of the median time-to-positivity at each 
time-point from 1000 simulations. The black dots connected with solid black lines are the 
observed median time-to-positivity (no model fit performed for this plot, the observed data is 
just overlaid the predictions). 
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Figure legend 
Supplementary Figure 2 Visual representation of the predicted and observed rifampicin non-
compartmental analysis area under plasma concentration time curve for 24 hours (AUC0-24h) 
for day 7 (left plot) and day 14 (right plot). Black dots with error bars are observed median 
and range of AUC0-24h and red dots with error bars are predicted median and range of AUC0-
24h. No model fitting was performed for the predictions, the observed data is just overlaid the 
predictions for reference. Red and blue shaded areas are the variability in the predicted 
median (red) and range (blue) shown as inter-quartile range from 1000 simulations. 
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Supplementary Table 1
Supplementary Table 1 Simulated day 7 AUC0-24h values used for prediction of high dose rifampicin 
Dose group 
(mg/kg) 
Day 7 AUC0-24h (h·mg/L) 
Observed Simulated* 
Median Max Min Median (IQR) Max (IQR) Min (IQR) 
10 43.0 53.0 34.0 42.8 (37.7-48.8) 83.2 (69.8-103.8) 22.7 (18.8-26.3) 
20 155.0 221.0 96.0 139.2 (128.3-151.0) 290.8 (248.4-343.8) 70.1 (61.3-79.8) 
25 178.0 380.0 134.0 172.7 (158.1-190.3) 375.9 (316.7-446.1) 88.2 (76.3-100.5) 
30 298.0 781.0 177.0 226.3 (208.2-247.6) 482.6 (414.2-580.8) 113.0 (97.8-130.1) 
35 321.0 555.0 145.0 286.2 (259.9-312.0) 616.1 (529.8-748.1) 142.7 (122.1-163.9) 
40 357.0 847.0 201.0 338.7 (308.9-373.0) 763.3 (642.9-957.4) 170.5 (145.4-194.7) 
45 - - - 413.2 (373.5-453.7) 950.5 (784.0-1218.6) 203.2 (174.5-232.8) 
50 - - - 481.4 (437.6-534.3) 1181.0 (964.6-1567.2) 237.4 (207.6-273.5) 
*All values are based on 1000 simulated trials 
Abbreviations: AUC0-24h, area under the plasma concentration-time curve during 24 hours; IQR, inter-quartile range 
